Acute Respiratory Distress During Stem Cell Infusion

  • Laura CoolingEmail author


  • Dextran is a standard and unique constituent used in cryopreservation of umbilical cord stem cells

  • About 0.01%–0.6% of the population are at risk for severe grade III-V anaphylactic reactions to dextran, including coronary vasospasm and takotsubo-type cardiotoxicity


DMSO Dextran Anaphylaxis Umbilical cord stem cells 


  1. 1.
    Cooling L, Gorlin J. Transfusion reactions associated with hematopoietic progenitor cell infusion. Transfusion reactions. Bethseda: AABB Press; 2012.Google Scholar
  2. 2.
    Zinderman CE, Landow L, Wise RP. Anaphylactoid reactions to dextran 40 and 70: reports to the United States Food and Drug Administration, 1969 to 2004. J Vasc Surg. 2006;43(5):1004–9.CrossRefGoogle Scholar
  3. 3.
    Cooling L, Sankar A, Mody R, Yanik G, Bonifant C, Choi SW. A severe umbilical cord stem cell infusion reaction due to dextran in an atopic pediatric patient. Bone Marrow Transplant. 2017;52(7):1051–3.CrossRefGoogle Scholar
  4. 4.
    Konuma T, Ooi J, Takahashi S, Tomonari A, Tsukada N, Kobayashi T, Sato A, Kato S, Kasahara S, Ebihara Y, Nagamura-Inoue T, Tsuji K, Tojo A, Asano S. Cardiovascular toxicity of cryopreserved cord blood cell infusion. Bone Marrow Transplant. 2008;41(10):861–5.CrossRefGoogle Scholar
  5. 5.
    Ma R, Kwan J, Ma D, Fay K. Acute life-threatening cardiovascular toxicity with umbilical cord blood infusion: the role of dextran. Am J Hematol. 2010;85:722–4.CrossRefGoogle Scholar
  6. 6.
    Choi S, Hoffmann S, Cooling L. Another case of acute cardiopulmonary toxicity with cord blood infusion: is dextran the culprit? Transfusion. 2012;52:207–8.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of PathologyUniversity of MichiganAnn ArborUSA

Personalised recommendations